By otakuyassine3@gmail.com 
Jackson Grant Investment Advisers Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 6.2% in the 4th quarter, Holdings Channel reports. The fund owned 9,824 shares of the biopharmaceutical company’s stock after selling 648 shares during the quarter. Jackson Grant Investment Advisers Inc.’s holdings in Pfizer were worth $261,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the 4th quarter worth approximately $26,000. Gladius Capital Management LP increased its position in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares in the last quarter. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer during the third quarter worth $35,000. Joseph Group Capital Management lifted its position in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 771 shares in the last quarter. Finally, Sugar Maple Asset Management LLC bought a new position in Pfizer during the 4th quarter worth about $43,000. Institutional investors and hedge funds own 68.36% of the company’s stock.
Pfizer Trading Up 2.3 %
Pfizer stock opened at $26.46 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50-day simple moving average of $26.27 and a 200 day simple moving average of $27.79. The stock has a market capitalization of $149.94 billion, a P/E ratio of 35.76, a PEG ratio of 0.66 and a beta of 0.64. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.
Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the firm earned $0.10 EPS. The firm’s revenue was up 24.7% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current year.
Pfizer Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.50%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 232.44%.
Analysts Set New Price Targets
PFE has been the topic of a number of research reports. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Guggenheim cut their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $31.92.
Check Out Our Latest Research Report on Pfizer
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.